Who
David Pauling
Chief Admin. Ofcr. & GC
Company insider
Files Form 4 as: Chief Admin. Ofcr. & GC, Sutro Biopharma.
In numbers
- Trades disclosed
- 30
- Buys
- 1
- Sells
- 0
- Bought
- $10K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 4 Apr 2025
- Last trade
- 4 Mar 2026
- Last filed
- 6 Mar 2026
Companies traded
Activity over time
1 Oct 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Mar 2026filed 6 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code M | —675 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code F | $5,903277 at $21.31 | filing |
| 4 Mar 2026filed 6 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —675 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —675 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code M | —675 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code F | $5,903277 at $21.31 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,600 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,356 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,200 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,600 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code M | —2,356 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code F | $20K970 at $20.55 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,356 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code M | —2,356 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code F | $20K970 at $20.55 | filing |
| 2 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,200 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code M | —500 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code M | —842 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Code F | $11K551 at $20.47 | filing |
| 1 Mar 2026filed 3 Mar 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —500 at $0.00 | filing |
News
Tenaya Therapeutics (NASDAQ:TNYA) versus Sutro Biopharma (NASDAQ:STRO) Head-To-Head ComparisonSTRO · themarketsdaily.com · 20 Oct 2026
0 headlines in the last 90 days name David Pauling; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.